Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Realgar-Indigo Naturalis Formula + retinoic acid
- Development stage
- Unknown
- Lead developer
- Harbin Sanlian Pharmaceutical
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Compound Realgar-Indigo Naturalis Formula + retinoic acid is a combination therapy used primarily for the treatment of acute promyelocytic leukemia (APL). The regimen consists of an oral traditional Chinese medicine-based formulation known as Realgar-Indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA). RIF contains realgar (tetraarsenic tetrasulfide), Indigo naturalis, Salvia miltiorrhiza, and Pseudostellaria heterophylla. Its main active ingredients are tetraarsenic tetrasulfide (from realgar), indirubin (from indigo), and tanshinone IIA (from Salvia miltiorrhiza). The mechanism involves degradation of the PML-RARα oncoprotein—a fusion protein specific to APL—by promoting its ubiquitination and subsequent proteasomal degradation. This leads to differentiation of leukemic cells and cell cycle arrest. All-trans retinoic acid further induces differentiation of promyelocytes by activating the retinoic acid receptor alpha pathway. The combination has demonstrated efficacy comparable to arsenic trioxide plus ATRA in clinical trials in China for both adult and pediatric patients with newly diagnosed or relapsed APL[2][6][8].
- Brand names
- Compound Huangdai
- Other names
- Compound Huangdai + all-trans retinoic acidRIF + ATRARealgar-Indigo naturalis formulation + ATRA
02
Targets
PML-RARA (PML-retinoic acid receptor alpha fusion protein)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on Compound Realgar-Indigo Naturalis Formula + retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound Realgar-Indigo Naturalis Formula + retinoic acid.